Insmed Incorporated — FY2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013. Insmed is a clinical-stage biopharmaceutical company focused on inhaled therapies for serious lung diseases. Its lead candidate, ARIKAYCE (liposomal amikacin for inhalation), was under development for NTM lung infections and Pseudomonas infections in cystic fibrosis (CF); it had no product sales. The 10-K was filed March 6, 2014.
Financial performance and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $11.5 million | $0 |
| Operating expenses | $66.5 million | $42.4 million |
| Operating loss | $55.0 million | $42.4 million |
| Net loss | $56.1 million | $41.4 million |
| Basic and diluted loss per share | $1.60 | $1.56 |
| Cash used in operating activities | $46.7 million | $31.0 million |
- The 2013 revenue was a one-time $11.5 million payment from Shire/Premacure for Insmed’s relinquishment of future IPLEX royalty rights; it was not recurring product revenue.
- R&D expense rose 48.7% to $44.3 million, mainly reflecting clinical development of ARIKAYCE. G&A increased to $22.2 million from $12.7 million, including higher compensation, consulting and professional fees. Stock-based compensation was $8.7 million, versus $3.0 million.
- Cash and cash equivalents were $113.9 million at year-end, compared with $90.8 million in cash plus a $2.2 million certificate of deposit at year-end 2012. Working capital was $99.7 million. Management said funds were sufficient for 2014, while noting future financing could be needed.
- Operating cash use was $46.7 million; excluding the Shire/Premacure payment, it would have been $58.2 million. The $67.0 million net proceeds from a July 2013 stock offering were the primary source of the year’s cash increase.
- Debt was $20.0 million face value, bearing 9.25% interest; balance-sheet debt was $19.6 million net of discounts and current classification. Principal maturity was January 2016. Principal payments were deferred to July 2014, with a further extension possible subject to a fee and positive NTM phase 2 data.
- Operating margins and profitability are not meaningful measures for this pre-commercial company; Insmed reported no product revenue and an accumulated deficit of $391.6 million. Total assets were $176.5 million and shareholders’ equity was $143.3 million.
Material changes and business developments
- ARIKAYCE’s phase 3 CF study in Europe and Canada met its primary endpoint of non-inferiority to twice-daily Tobi for change in lung function. The company planned European and Canadian regulatory filings in mid-2014; U.S. CF development plans were to be reassessed after NTM data.
- Enrollment of 90 patients in the U.S./Canada phase 2 NTM trial was complete; top-line results were expected in March 2014. Insmed planned a supportive open-label NTM study and regulatory discussions in the second quarter of 2014.
- The company entered a manufacturing agreement with Therapure in February 2014 to support larger-scale ARIKAYCE production. Existing manufacturer Althea’s agreement was due to expire in July 2014, and an extension was being negotiated.
- Insmed raised $67.0 million net through a July 2013 public equity offering; shares outstanding increased to 39.1 million at year-end from 31.5 million in 2012.
- Insmed received a $1.2 million tax benefit from selling New Jersey tax-loss carryforwards. Its federal NOL carryforwards were approximately $398.7 million, but usage may be substantially limited under Section 382.
Outlook, risks, contingencies and unusual items
- Management expected substantial operating losses and cash needs to continue, with no significant revenue anticipated unless ARIKAYCE receives approval and is commercialized. The company was preparing for potential launches but gave no revenue, earnings or launch-date guidance.
- ARIKAYCE remained unapproved. Regulatory success, clinical outcomes, acceptable labeling and reimbursement were uncertain. In long-term rat testing, 2 of 120 rats at the highest dose developed lung tumors; human relevance was unknown. FDA clinical holds imposed in 2011 were lifted in 2012, and a 2013 dog study found no evidence of neoplasia or proliferative changes.
- Supply is a significant execution risk: ARIKAYCE and its optimized eFlow nebulizer depended on third parties, and the company identified PARI as its sole nebulizer supplier. Commercial-scale manufacturing capability and required regulatory clearances remained to be established.
- Insmed had a $20 million Hercules loan secured by company assets other than intellectual property, with restrictive covenants and potential default remedies. Total contractual obligations were $27.6 million, including debt, interest, leases and capital leases; this excluded uncertain collaboration milestones and royalties.
- The Transave appraisal case involving approximately 7.77 million dissenting shares remained unresolved; trial was scheduled for April 2014. Insmed said the loss range could not be estimated. The Cacchillo litigation was dismissed, with the dismissal affirmed in January 2014.
- In 2013, Insmed identified excess equity awards of approximately 1.4 million shares caused by exceeding plan sub-limits. Shareholders approved the grants in May 2013, after which related liabilities were reclassified to equity. Management and the auditor reported effective internal controls as of year-end 2013; a material weakness had been reported for 2012.
- Auditors issued unqualified opinions on the consolidated financial statements and internal control over financial reporting.
Important facts for investors to verify
- Results and regulatory feedback from the NTM phase 2 trial, and the resulting development and filing path for both NTM and CF indications.
- Whether Althea manufacturing is extended and Therapure successfully transfers and scales production, and whether PARI can supply and obtain clearance for the nebulizer.
- Cash burn relative to the $113.9 million year-end cash balance, financing needs, and any dilution from future capital raises or equity awards.
- Debt repayment timing and covenants, including conditions for any further interest-only extension.
- Potential costs or outcomes of the Transave appraisal litigation and the effects of Section 382 limits on tax attributes.